GleamWall
中文EN

DFTX Definium Therapeutics, Inc.

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1813814 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-100.8%
TTM EPS YoY-47.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-61.4%
ROA-51.5%
ROIC (approx.)-43.9%
Asset turnover—

Leverage & solvency

Liabilities / assets9.9%
Debt / equity0.04x
Current ratio15.53x
Interest coverage-51.91x

Cash quality & payout

Operating cash flow / net income0.57x
Accruals ratio-22.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$117.67M$65.30M
SG&A expense$48.64M$38.62M
Operating income-$166.31M-$103.92M
Interest expense$5.48M$2.28M
Pretax income-$183.79M-$108.68M
Income tax$0—
Net income-$183.79M-$108.68M
EPS (basic)-2.06-1.54
EPS (diluted)-2.06-1.54
Weighted avg. shares (diluted)89.33M70.46M
Balance sheet
Cash & equivalents$257.84M$273.74M
Short-term investments$153.76M$0
Current assets$419.32M$281.62M
Goodwill$19.92M$19.92M
Intangibles—$0
Total assets$440.10M$302.15M
Current liabilities$66.70M$38.85M
Long-term debt$40.58M$21.85M
Total debt$40.58M$21.85M
Total liabilities$107.77M$60.70M
Shareholders' equity$332.33M$241.45M
Net debt-$217.26M-$251.89M
Shares outstanding98.78M75.10M
Cash flow statement
Operating cash flow-$131.56M-$79.13M
Investing cash flow-$151.61M$0
Financing cash flow$267.27M$253.20M
Stock-based compensation$20.10M$16.91M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.